Phio Pharmaceuticals Stock Forecast, Price & News

-0.03 (-1.35 %)
(As of 06/23/2021 12:09 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,236 shs
Average Volume1.11 million shs
Market Capitalization$29.64 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PHIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Phio Pharmaceuticals logo

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that prevent cancer cells from inactivating T cells and attack the cancer. It has collaboration with AgonOx, Inc. on clinical development of novel immunotherapy drugs targeting key regulators of the immune response to cancer. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.20 out of 5 stars

Medical Sector

967th out of 2,105 stocks

Pharmaceutical Preparations Industry

471st out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions

Is Phio Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Phio Pharmaceuticals stock.
View analyst ratings for Phio Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Phio Pharmaceuticals?

Wall Street analysts have given Phio Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Phio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Phio Pharmaceuticals?

Phio Pharmaceuticals saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 1,330,000 shares, an increase of 100.8% from the April 29th total of 662,200 shares. Based on an average daily volume of 1,000,000 shares, the short-interest ratio is currently 1.3 days. Currently, 10.0% of the company's stock are sold short.
View Phio Pharmaceuticals' Short Interest

When is Phio Pharmaceuticals' next earnings date?

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Phio Pharmaceuticals

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced its quarterly earnings results on Thursday, March, 25th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.42) by $0.01.
View Phio Pharmaceuticals' earnings history

How has Phio Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Phio Pharmaceuticals' stock was trading at $2.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PHIO shares have decreased by 20.9% and is now trading at $2.19.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PHIO?

1 analysts have issued 12 month target prices for Phio Pharmaceuticals' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Phio Pharmaceuticals' stock price to reach $6.00 in the next year. This suggests a possible upside of 174.0% from the stock's current price.
View analysts' price targets for Phio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Phio Pharmaceuticals' key executives?

Phio Pharmaceuticals' management team includes the following people:
  • Dr. Gerrit Dispersyn Ph.D., Dr. Med. Sc, Pres, CEO & Director (Age 46, Pay $583.14k)
  • Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 35)

Who are some of Phio Pharmaceuticals' key competitors?

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

Who are Phio Pharmaceuticals' major shareholders?

Phio Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.98%), Geode Capital Management LLC (0.65%), Dimensional Fund Advisors LP (0.26%) and Virtu Financial LLC (0.11%). Company insiders that own Phio Pharmaceuticals stock include Gerrit Dispersyn and Robert L Ferrara.
View institutional ownership trends for Phio Pharmaceuticals

Which institutional investors are buying Phio Pharmaceuticals stock?

PHIO stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, GSA Capital Partners LLP, Virtu Financial LLC, and Dimensional Fund Advisors LP. Company insiders that have bought Phio Pharmaceuticals stock in the last two years include Gerrit Dispersyn, and Robert L Ferrara.
View insider buying and selling activity for Phio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $2.19.

How much money does Phio Pharmaceuticals make?

Phio Pharmaceuticals has a market capitalization of $29.64 million and generates $20,000.00 in revenue each year. The company earns $-8,790,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis.

How many employees does Phio Pharmaceuticals have?

Phio Pharmaceuticals employs 10 workers across the globe.

What is Phio Pharmaceuticals' official website?

The official website for Phio Pharmaceuticals is

Where are Phio Pharmaceuticals' headquarters?

Phio Pharmaceuticals is headquartered at 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at 508-767-3861 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.